Cargando…
Atypical antipsychotics as add-on treatment in late-life depression
BACKGROUND: Second-generation antipsychotics (SGAs) have been used in the augmentation of treatment-resistant depression. However, little is known about their effectiveness, tolerability, and adverse events in the treatment of late-life depression, which were the aim of this study. METHODS: The retr...
Autores principales: | Cakir, Sibel, Senkal, Zeynep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025007/ https://www.ncbi.nlm.nih.gov/pubmed/27672315 http://dx.doi.org/10.2147/CIA.S114244 |
Ejemplares similares
-
Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia
por: Raveendranthan, Dhanya, et al.
Publicado: (2018) -
New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022) -
A Comment on “Add-on Aripiprazole for Atypical Antipsychotic-induced, Clinically Significant Hyperprolactinemia”
por: Naguy, Ahmed
Publicado: (2018) -
Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020) -
Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes
por: Spielmans, Glen I., et al.
Publicado: (2013)